Updated Reviewed

Appendix B: Acronyms

General Terms

Acronym Term
°C degrees Celsius
°F degrees Fahrenheit
% v volume
25-OH-vitamin D 25-hydroxy vitamin D
AE adverse effect
AHR adjusted hazard ratio
ALT alanine aminotransferase
ANC absolute neutrophil count
app mobile application
ART antiretroviral therapy
ARV antiretroviral
ASCVD atherosclerotic cardiovascular disease
AST aspartate aminotransferase
AUC area under the curve
AUC0-12h area under the curve at 12 hours post-dose
AUC24h area under the curve at 24 hours post-dose
AUCtau area under the curve
AV atrioventricular
BCRP breast cancer resistance protein
BHIVA British HIV Association
BMD bone mineral density
BMI body mass index
BSA body surface area
C0h pre-dose concentration
C12h  concentration at 12 hours
C24h concentration at 24 hours
CAR chimeric antigen receptor
Cavg average plasma concentration
CBC complete blood count
CD4 CD4 T lymphocyte
CDC Centers for Disease Control and Prevention
CI confidence interval
CK creatine kinase
Cmax maximum plasma concentration
Cmin minimum plasma concentration
CMV cytomegalovirus
CNS central nervous system
Cr creatinine
CrCl creatinine clearance
CT continuous therapy
Ctau concentration at the end of a dosing interval
Ctrough trough concentration
CTx C-telopeptide of type 1 collagen
CV coefficients of variation
CVDI cardiovascular disease
CYP cytochrome P
CYPB26 cytochrome P450 family 2 subfamily B member 6
DAIDS Division of AIDS (NIAID)
DBS dried blood spot
dL deciliter
DM diabetes mellitus
DNA deoxyribonucleic acid
DOT directly observed therapy
DRESS drug reaction (or rash) with eosinophilia and systemic symptoms
DSG delayed switch group
DSMB Data Safety Monitoring Board
DT dispersible tablet
DXA dual energy x-ray absorptiometry
E2D2 Every Dose, Every Day [Toolkit and App]
EBV Epstein-Barr virus
EC enteric-coated
EC50 half maximal effective concentration
ECG  electrocardiogram
EEG electroencephalogram
eGFR estimated glomerular filtration rate
EM erythema multiforme or extensive metabolizers
FCT film-coated tablet
FDA Food and Drug Administration
FDC fixed-dose combination
fL femtoliter
FLP fasting lipid profile
fmol femtomole
FPG fasting plasma glucose
g gram
g/dL grams per deciliter
G6PD glucose-6-phosphate dehydrogenase
GA gestational age
GFR glomerular filtration rate
GI gastrointestinal
GLSM geometric least squares mean
GM geometric mean
GMR geometric mean ratio
gp glycoprotein
gp120 glycoprotein 120
h hour
HA height age
HAV hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HD high dose
HDL-C high-density lipoprotein cholesterol
Hgb hemoglobin
HgbA1c glycosylated hemoglobin
HHS Department of Health and Human Services
HIV RNA or HIV-1 RNA viral load
HLA human leukocyte antigen
HRSA Health Resources and Services Administration
HSR hypersensitivity reaction
HSV herpes simplex virus
IAS-USA International Antiviral Society-USA
IFPG impaired fasting plasma glucose
IGT impaired glucose tolerance
IM intramuscular
INSTI integrase strand transfer inhibitor
IQ inhibitory quotient
IQR interquartile range
IR insulin resistance
IRIS immune reconstitution inflammatory syndrome
ISG immediate switch group
IU international units
IV intravenous
IVIG intravenous immune globulin
kg kilogram
L liter
LAI long-acting injectable
LBW low birth weight
LDL low-density lipoprotein
LDL-C low-density lipoprotein cholesterol
LFT liver function test
Log10 the logarithm to the base 10
LS lipodystrophy syndrome
LVH left ventricular hypertrophy
m2 square meter
mcg  microgram
MCV mean cell volume
mDAART modified directly administered ART
MEMS Medication Event Monitoring System
mg milligram
min minute
mL milliliter
mm millimeter
mm3 cubic millimeter
mmol millimole
N/A not available or not applicable
NASBA nucleic acid sequence-based amplification
NAT nucleic acid test
ng nanogram
NHLBI National Heart, Lung, and Blood Institute
NIH National Institutes of Health
nM nanometer
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NTD neural tube defect
OARAC Office of AIDS Research Advisory Council
OAT organic anion transporter
OATP organic anion transporter polypeptide
OBT optimized background therapy
OGTT oral glucose tolerance test
OI opportunistic infection
oz ounce
PA-IC95 protein-adjusted IC95
The Panel the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV
PBMC peripheral blood mononuclear cell
PCP Pneumocystis jirovecii pneumonia
PCR polymerase chain reaction
PEP post-exposure prophylaxis
PG plasma glucose
P-gp P-glycoprotein
PI protease inhibitor
PK pharmacokinetic
POC point of care
PPI proton pump inhibitor
PrEP pre-exposure prophylaxis
PUFA polyunsaturated fatty acid
py patient years
QTc corrected QT
RCT randomized controlled trial
RNA ribonucleic acid
RPG random plasma glucose
RR relative risk
RT-PCR reverse transcription polymerase chain reaction
SAM severe acute malnutrition
SCT short-cycle therapy
SD standard deviation
SJS Stevens-Johnson syndrome
SM slow metabolizers
SMR sexual maturity rating
SMS short message service
SOC standard of care
SQ subcutaneous
STI sexually transmitted infection
STR single-tablet regimen
T½ half-life
TB tuberculosis
TBLH total body less head
TC total cholesterol
TDM therapeutic drug monitoring
TEN toxic epidermal necrolysis
TG triglyceride
TMA transcription-mediated amplification
Tmax time to reach maximum concentration
U=U Undetectable = Untransmittable
UGT uridine diphosphate glucuronosyltransferase
UGT1A uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex
ULN upper limit of normal
v/v volume per volume
w weight
WHO World Health Organization
XR extended release


Appendix B: Acronyms


General Terms
°Cdegrees Celsius
°Fdegrees Fahrenheit
% vvolume
25-OH-vitamin D25-hydroxy vitamin D
AEadverse effect
AHRadjusted hazard ratio
ALTalanine aminotransferase
ANCabsolute neutrophil count
appmobile application
ARTantiretroviral therapy
ASCVDatherosclerotic cardiovascular disease
ASTaspartate aminotransferase
AUCarea under the curve
AUC0-12harea under the curve at 12 hours post-dose
AUC24harea under the curve at 24 hours post-dose
AUCtauarea under the curve
BCRPbreast cancer resistance protein
BHIVABritish HIV Association
BMDbone mineral density
BMIbody mass index
BSAbody surface area
C0hpre-dose concentration
C12h concentration at 12 hours
C24hconcentration at 24 hours
CARchimeric antigen receptor
Cavgaverage plasma concentration
CBCcomplete blood count
CD4CD4 T lymphocyte
CDCCenters for Disease Control and Prevention
CIconfidence interval
CKcreatine kinase
Cmaxmaximum plasma concentration
Cminminimum plasma concentration
CNScentral nervous system
CrClcreatinine clearance
CTcontinuous therapy
Ctauconcentration at the end of a dosing interval
Ctroughtrough concentration
CTxC-telopeptide of type 1 collagen
CVcoefficients of variation
CVDIcardiovascular disease
CYPcytochrome P
CYPB26cytochrome P450 family 2 subfamily B member 6
DBSdried blood spot
DMdiabetes mellitus
DNAdeoxyribonucleic acid
DOTdirectly observed therapy
DRESSdrug reaction (or rash) with eosinophilia and systemic symptoms
DSGdelayed switch group
DSMBData Safety Monitoring Board
DTdispersible tablet
DXAdual energy x-ray absorptiometry
E2D2Every Dose, Every Day [Toolkit and App]
EBVEpstein-Barr virus
EC50half maximal effective concentration
ECG electrocardiogram
eGFRestimated glomerular filtration rate
EMerythema multiforme or extensive metabolizers
FCTfilm-coated tablet
FDAFood and Drug Administration
FDCfixed-dose combination
FLPfasting lipid profile
FPGfasting plasma glucose
g/dLgrams per deciliter
G6PDglucose-6-phosphate dehydrogenase
GAgestational age
GFRglomerular filtration rate
GLSMgeometric least squares mean
GMgeometric mean
GMRgeometric mean ratio
gp120glycoprotein 120
HAheight age
HAVhepatitis A virus
HBVhepatitis B virus
HCVhepatitis C virus
HDhigh dose
HDL-Chigh-density lipoprotein cholesterol
HgbA1cglycosylated hemoglobin
HHSDepartment of Health and Human Services
HIV RNA or HIV-1 RNAviral load
HLAhuman leukocyte antigen
HRSAHealth Resources and Services Administration
HSRhypersensitivity reaction
HSVherpes simplex virus
IAS-USAInternational Antiviral Society-USA
IFPGimpaired fasting plasma glucose
IGTimpaired glucose tolerance
INSTIintegrase strand transfer inhibitor
IQinhibitory quotient
IQRinterquartile range
IRinsulin resistance
IRISimmune reconstitution inflammatory syndrome
ISGimmediate switch group
IUinternational units
IVIGintravenous immune globulin
LAIlong-acting injectable
LBWlow birth weight
LDLlow-density lipoprotein
LDL-Clow-density lipoprotein cholesterol
LFTliver function test
Log10the logarithm to the base 10
LSlipodystrophy syndrome
LVHleft ventricular hypertrophy
m2square meter
mcg microgram
MCVmean cell volume
mDAARTmodified directly administered ART
MEMSMedication Event Monitoring System
mm3cubic millimeter
N/Anot available or not applicable
NASBAnucleic acid sequence-based amplification
NATnucleic acid test
NHLBINational Heart, Lung, and Blood Institute
NIHNational Institutes of Health
NNRTInon-nucleoside reverse transcriptase inhibitor
NRTInucleoside reverse transcriptase inhibitor
NTDneural tube defect
OARACOffice of AIDS Research Advisory Council
OATorganic anion transporter
OATPorganic anion transporter polypeptide
OBToptimized background therapy
OGTToral glucose tolerance test
OIopportunistic infection
PA-IC95protein-adjusted IC95
The Panelthe Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV
PBMCperipheral blood mononuclear cell
PCPPneumocystis jirovecii pneumonia
PCRpolymerase chain reaction
PEPpost-exposure prophylaxis
PGplasma glucose
PIprotease inhibitor
POCpoint of care
PPIproton pump inhibitor
PrEPpre-exposure prophylaxis
PUFApolyunsaturated fatty acid
pypatient years
QTccorrected QT
RCTrandomized controlled trial
RNAribonucleic acid
RPGrandom plasma glucose
RRrelative risk
RT-PCRreverse transcription polymerase chain reaction
SAMsevere acute malnutrition
SCTshort-cycle therapy
SDstandard deviation
SJSStevens-Johnson syndrome
SMslow metabolizers
SMRsexual maturity rating
SMSshort message service
SOCstandard of care
STIsexually transmitted infection
STRsingle-tablet regimen
TBLHtotal body less head
TCtotal cholesterol
TDMtherapeutic drug monitoring
TENtoxic epidermal necrolysis
TMAtranscription-mediated amplification
Tmaxtime to reach maximum concentration
U=UUndetectable = Untransmittable
UGTuridine diphosphate glucuronosyltransferase
UGT1Auridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex
ULNupper limit of normal
v/vvolume per volume
WHOWorld Health Organization
XRextended release


Download Guidelines